a2 Milk Cuts FY26 Margin Outlook as China IMF Supply Chain Disruption Weighs on Near-Term Performance

About The a2 Milk Company Limited

The a2 Milk Company Limited (ASX: A2M) is a dairy and nutrition company with a strong focus on infant milk formula, milk and nutritional products sold under the a2 brand. In this update, the group focused on its China infant milk formula business, where demand has remained strong but temporary supply chain disruption is expected to weigh on fourth-quarter availability, revenue timing and FY26 margins. The company also said its supply chain transformation programme at a2 Pōkeno remains on track ahead of a planned production ramp-up in the first half of FY27.

Demand remains strong, but supply has become the constraint

The most important feature of the update is that a2 Milk is not dealing with a demand problem. The company said demand for the a2 brand remained strong through the third quarter across all product categories and regions, with positive year-to-date offtake trends similar to or better than those seen in the first half. That distinction matters because it suggests the softness now expected in FY26 is being driven by supply chain friction rather than weakening consumer interest.

China label a2 至初 infant milk formula continues to perform well, with early-stage new user recruitment improving after supply constraints in the first quarter. The company said this was supported by the My Little Pony marketing campaign. Later-stage growth also benefited from earlier share gains, natural stage transition and the success of the company’s new kids nutrition product. English label demand also remained strong, underpinned by growth in a2 Platinum and a2 Genesis across all stages, particularly through the cross-border e-commerce channel.

That backdrop is strategically significant because it points to continuing brand momentum in China, which remains one of the company’s most important profit pools. In other words, the current downgrade is occurring despite strong consumer demand rather than because of any loss of competitive relevance.

China label availability is being squeezed by several simultaneous pressures

The operational challenge is that several supply chain issues have hit at once. The company said it is currently experiencing temporary in-market product availability issues, primarily in China label infant milk formula at distributor and retailer level. These shortfalls are being driven by a combination of strong demand, freight bottlenecks, low inventory levels, slower product release times and tighter customs clearance.

Strong demand has been amplified by international competitor product recalls, which have helped support demand for imported a2 infant milk formula products. Freight has also become more difficult, with the availability and cost of additional air freight required to accelerate shipments to China being indirectly affected by the Middle East conflict, while sea freight capacity has shown variability. At the same time, inventory levels have remained low through FY26 because of past Synlait manufacturing challenges and other operational issues. Although production at Synlait has recently returned to target levels, the company still faces a significant backlog of unfilled purchase orders and now has less catch-up capacity following the sale of Synlait’s North Island assets.

Quality assurance and import timing have also become more complex. Emerging standards tied to enhanced cereulide testing are extending product release times, while additional customs clearance requirements, including higher inspection and sampling rates across the industry, are delaying product availability further. Taken together, these pressures are now expected to materially affect China label IMF availability during the fourth quarter, especially through April and May.

English label is more resilient, but not completely insulated

The disruption is not uniform across the whole infant milk formula portfolio. The company said English label product is exposed to some extent to the same issues, particularly the additional clearance requirements, but is not expected to be as significantly impacted during this period. That offers some degree of offset within the broader IMF business, although not enough to prevent pressure on group guidance.

There is, however, a near-term issue for a2 Genesis, which accounts for about 6 per cent of cross-border e-commerce sales. That product is also currently facing availability issues in CBEC channels because of strong demand. The company expects this to be addressed shortly through the resumption of production at a2 Pōkeno, following the completion of planned canning line capital works and maintenance.

This is relevant because it shows a2 Milk still has avenues to improve supply responsiveness over time, particularly as Pōkeno ramps up. Even so, those improvements are unlikely to fully offset the immediate fourth-quarter timing issues now affecting FY26.

The Pōkeno transformation remains a key medium-term lever

A2 Milk’s broader supply chain transformation programme at a2 Pōkeno remains on track, and that is an important part of the medium-term story. The company said capital upgrade works, recruitment and capability building, product trials and the China label registration amendment process are all progressing as planned, ahead of an expected ramp-up in production in the first half of FY27.

That matters because the current issues highlight the strategic value of having stronger internal production capability and a more flexible end-to-end supply chain. If Pōkeno ramps successfully, it should improve the company’s ability to support demand, reduce bottlenecks and limit future reliance on constrained manufacturing catch-up.

For now, though, the short-term impact is difficult to avoid. The company said the issues have evolved rapidly and remain subject to uncertainty, especially in relation to freight variability, customs clearance and the possibility of further indirect effects stemming from the Middle East conflict.

FY26 guidance is now lower across revenue, margin and cash conversion

The cumulative effect of these one-off and timing-related issues is now expected to affect performance against FY26 guidance. The group now expects revenue growth on a continuing operations basis to be in the low to mid double digits, down from earlier guidance for mid double-digit growth. EBITDA margin is now expected to be about 14.0 per cent to 14.5 per cent, compared with previous guidance of 15.5 per cent to 16.0 per cent. Depreciation and amortisation is expected to be about NZ$20 million, while interest income is also expected to be lower because of lower market rates and net transaction cash outflows.

Most notably, NPAT is now expected to be similar to down on FY25 reported levels, whereas management had previously expected growth. Cash conversion is also now expected to be about 50 per cent rather than 80 per cent, reflecting the later timing of infant milk formula sales and delayed cash receipts into FY27. Capital expenditure remains expected to be around NZ$60 million to NZ$80 million.

This guidance reset is meaningful because it affects both profitability and cash flow, even though the underlying demand profile remains supportive. It also means investors will likely be focused not just on fourth-quarter trading, but on how much demand is deferred into FY27 rather than lost outright.

Outlook

A2 Milk’s near-term challenge is clearly supply, not demand. The brand continues to perform strongly in China, but a combination of production backlog, freight disruption, extended quality release times and tighter customs processes is expected to weigh on fourth-quarter availability and FY26 performance. The company continues to treat these pressures as largely timing-related and one-off, while maintaining brand investment and progressing the Pōkeno transformation ahead of a planned first-half FY27 production ramp-up. If supply conditions normalise and catch-up capacity improves, the current disruption could prove temporary, but for now the business is likely to finish FY26 with lower margin, weaker cash conversion and more earnings pressure than previously expected.